Abstract
The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.
| Original language | English |
|---|---|
| Pages (from-to) | 1097-1107 |
| Journal | Glycobiology |
| Volume | 21 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2011 |
Subject classification (UKÄ)
- Biochemistry and Molecular Biology
Free keywords
- monoclonal antibody
- in vivo therapy
- antigen
- Tn
- anti-carbohydrate
- biomarker
